HUTCHMED China Ltd (HCM) - Net Assets
Based on the latest financial reports, HUTCHMED China Ltd (HCM) has net assets worth GBX1.25 Billion GBX (≈ $152.24K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX1.75 Billion ≈ $213.30K USD) and total liabilities (GBX501.83 Million ≈ $61.06K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore HCM asset base for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX1.25 Billion |
| % of Total Assets | 71.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | 20.21% |
| 10-Year Change | 512.35% |
| Growth Volatility | 47.38 |
HUTCHMED China Ltd - Net Assets Trend (2005–2025)
This chart illustrates how HUTCHMED China Ltd's net assets have evolved over time, based on quarterly financial data. Check HCM intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for HUTCHMED China Ltd (2005–2025)
The table below shows the annual net assets of HUTCHMED China Ltd from 2005 to 2025. For live valuation and market cap data, see HCM market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | GBX1.25 Billion ≈ $152.03K |
+61.89% |
| 2024-12-31 | GBX771.85 Million ≈ $93.91K |
+3.83% |
| 2023-12-31 | GBX743.39 Million ≈ $90.45K |
+16.73% |
| 2022-12-31 | GBX636.87 Million ≈ $77.49K |
-38.73% |
| 2021-12-31 | GBX1.04 Billion ≈ $126.48K |
+100.31% |
| 2020-12-31 | GBX518.95 Million ≈ $63.14K |
+65.85% |
| 2019-12-31 | GBX312.90 Million ≈ $38.07K |
-24.10% |
| 2018-12-31 | GBX412.25 Million ≈ $50.16K |
-14.99% |
| 2017-12-31 | GBX484.97 Million ≈ $59.01K |
+137.66% |
| 2016-12-31 | GBX204.06 Million ≈ $24.83K |
+99.52% |
| 2015-12-31 | GBX102.28 Million ≈ $12.44K |
-14.69% |
| 2014-12-31 | GBX119.88 Million ≈ $14.59K |
+14.35% |
| 2013-12-31 | GBX104.84 Million ≈ $12.76K |
+25.33% |
| 2012-12-31 | GBX83.65 Million ≈ $10.18K |
+8.17% |
| 2011-12-31 | GBX77.33 Million ≈ $9.41K |
+12.39% |
| 2010-12-31 | GBX68.81 Million ≈ $8.37K |
-8.62% |
| 2009-12-31 | GBX75.30 Million ≈ $9.16K |
-10.81% |
| 2008-12-31 | GBX84.43 Million ≈ $10.27K |
-13.50% |
| 2007-12-31 | GBX97.61 Million ≈ $11.88K |
-11.25% |
| 2006-12-31 | GBX109.98 Million ≈ $13.38K |
+492.65% |
| 2005-12-31 | GBX-28.01 Million ≈ $-3.41K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to HUTCHMED China Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34398216160.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX87.11 Million | 7.05% |
| Other Comprehensive Income | GBX-4.53 Million | -0.37% |
| Other Components | GBX1.53 Billion | 123.91% |
| Total Equity | GBX1.24 Billion | 100.00% |
HUTCHMED China Ltd Competitors by Market Cap
The table below lists competitors of HUTCHMED China Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Greenwing Resources Ltd
AU:GW1
|
$17.38 Million |
|
Job Solution Sweden Holding AB
ST:JOBS
|
$17.38 Million |
|
New Zealand Energy Corp
V:NZ
|
$17.38 Million |
|
Astral Asia Bhd
KLSE:7054
|
$17.38 Million |
|
Trilogiq
PA:ALTRI
|
$17.36 Million |
|
Pungkang Co. Ltd
KQ:093380
|
$17.35 Million |
|
Keyware Technologies NV
BR:KEYW
|
$17.34 Million |
|
Polylite Taiwan Co Ltd
TWO:1813
|
$17.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HUTCHMED China Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 759,929,000 to 1,236,237,946, a change of 476,308,946 (62.7%).
- Net income of 457,021,070 contributed positively to equity growth.
- New share issuances of 1,578,000 increased equity.
- Other comprehensive income increased equity by 7,059,181.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX457.02 Million | +36.97% |
| Share Issuances | GBX1.58 Million | +0.13% |
| Other Comprehensive Income | GBX7.06 Million | +0.57% |
| Other Changes | GBX10.65 Million | +0.86% |
| Total Change | GBX- | 62.68% |
Book Value vs Market Value Analysis
This analysis compares HUTCHMED China Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 117.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | GBX-0.09 | GBX166.00 | x |
| 2006-12-31 | GBX0.23 | GBX166.00 | x |
| 2007-12-31 | GBX0.18 | GBX166.00 | x |
| 2008-12-31 | GBX0.15 | GBX166.00 | x |
| 2009-12-31 | GBX0.13 | GBX166.00 | x |
| 2010-12-31 | GBX0.12 | GBX166.00 | x |
| 2011-12-31 | GBX0.12 | GBX166.00 | x |
| 2012-12-31 | GBX0.13 | GBX166.00 | x |
| 2013-12-31 | GBX0.17 | GBX166.00 | x |
| 2014-12-31 | GBX0.18 | GBX166.00 | x |
| 2015-12-31 | GBX0.15 | GBX166.00 | x |
| 2016-12-31 | GBX0.31 | GBX166.00 | x |
| 2017-12-31 | GBX0.75 | GBX166.00 | x |
| 2018-12-31 | GBX0.59 | GBX166.00 | x |
| 2019-12-31 | GBX0.43 | GBX166.00 | x |
| 2020-12-31 | GBX0.69 | GBX166.00 | x |
| 2021-12-31 | GBX1.25 | GBX166.00 | x |
| 2022-12-31 | GBX0.77 | GBX166.00 | x |
| 2023-12-31 | GBX0.84 | GBX166.00 | x |
| 2024-12-31 | GBX0.87 | GBX166.00 | x |
| 2025-12-31 | GBX1.42 | GBX166.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HUTCHMED China Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 36.97%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 83.30%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.42x
- Recent ROE (36.97%) is above the historical average (-7.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 0.00% | -17.90% | 0.60x | 0.00x | GBX-3.41 Million |
| 2006 | -9.33% | -19.05% | 0.38x | 1.29x | GBX-19.90 Million |
| 2007 | -19.04% | -26.40% | 0.51x | 1.41x | GBX-26.22 Million |
| 2008 | -23.63% | -20.41% | 0.74x | 1.57x | GBX-25.27 Million |
| 2009 | -13.28% | -7.88% | 0.87x | 1.94x | GBX-15.34 Million |
| 2010 | -11.53% | -5.10% | 0.84x | 2.69x | GBX-12.82 Million |
| 2011 | 1.10% | 0.43% | 0.86x | 3.01x | GBX-5.77 Million |
| 2012 | 5.15% | 1.86% | 0.93x | 2.97x | GBX-3.42 Million |
| 2013 | 6.66% | 12.87% | 0.25x | 2.09x | GBX-2.97 Million |
| 2014 | 5.66% | 5.85% | 0.42x | 2.31x | GBX-4.11 Million |
| 2015 | 9.59% | 4.49% | 0.78x | 2.76x | GBX-342.60K |
| 2016 | 6.35% | 5.41% | 0.63x | 1.86x | GBX-6.73 Million |
| 2017 | -5.79% | -11.08% | 0.40x | 1.29x | GBX-72.91 Million |
| 2018 | -19.23% | -34.94% | 0.40x | 1.37x | GBX-113.70 Million |
| 2019 | -36.00% | -50.60% | 0.44x | 1.61x | GBX-132.48 Million |
| 2020 | -25.97% | -55.15% | 0.31x | 1.50x | GBX-174.14 Million |
| 2021 | -19.72% | -54.66% | 0.26x | 1.39x | GBX-293.34 Million |
| 2022 | -59.12% | -84.62% | 0.41x | 1.69x | GBX-421.87 Million |
| 2023 | 13.80% | 12.03% | 0.65x | 1.75x | GBX27.73 Million |
| 2024 | 4.96% | 5.99% | 0.49x | 1.68x | GBX-38.26 Million |
| 2025 | 36.97% | 83.30% | 0.31x | 1.42x | GBX333.40 Million |
Industry Comparison
This section compares HUTCHMED China Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,954,893,785
- Average return on equity (ROE) among peers: -50.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HUTCHMED China Ltd (HCM) | GBX1.25 Billion | 0.00% | 0.40x | $17.36 Million |
| Allergy Therapeutics (AGY) | $29.96 Million | -8.28% | 0.91x | $4.47 Million |
| Animalcare Group Plc (ANCR) | $5.68 Million | 4.93% | 0.18x | $2.80 Million |
| Alliance Pharma plc (APH) | $217.87 Million | -15.21% | 0.90x | $4.26 Million |
| Celadon Pharmaceuticals PLC (CEL) | $6.41 Million | -74.61% | 0.03x | $112.25K |
| Chill Brands Group PLC (CHLL) | $2.11 Million | -387.19% | 0.58x | $139.98K |
| Eco Animal Health Group Plc (EAH) | $55.70 Million | 2.22% | 0.15x | $824.39K |
| Hikma Pharmaceuticals PLC (HIK) | $750.30 Million | 13.17% | 0.49x | $42.63 Million |
| Haleon PLC (HLN) | $16.73 Billion | 6.27% | 1.04x | $393.88 Million |
| Indivior PLC (INDV) | $-203.00 Million | 0.00% | 0.00x | $18.79 Million |
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more